ABSTRACT The effects of milrinone and captopril on ventricular performance, renal blood flow, and femoral vein oxygen content were compared in 11 patients with severe chronic heart failure. The increase in stroke volume index was greater with milrinone than with captopril (28 -+ 7 vs 24 + 7 ml/m2; p < .05), while pulmonary capillary wedge pressures fell similarly (19 -+ 10 vs 21 7 mm Hg). Mean systemic arterial pressure decreased significantly from 84 + 10 to 73 + 11 mm Hg (p < .05) with captopril but did not with milrinone. Neither drug changed heart rate significantly. Although milrinone produced a greater improvement in ventricular performance than captopril, renal blood flow increased similarly with both drugs from 289 78 to 417 + 1 1 ml/min (p < .05) and from 278 ± 77 to 441 + 115 ml/min (p < .05), respectively. Femoral vein oxygen content was increased by milrinone from 7.9 2.6 to 9.8 + 3.0 ml/100 ml (p < .05) and was not changed by captopril. In seven additional patients, intravenous milrinone, administered at the peak effect of captopril, further augmented stroke volume index from 24 + 6 to 32 + 6 mI/M2 (p < .05) and tended to reduce pulmonary capillary wedge pressure further from 20 ± 8 to 18 ± 9 mm Hg (p = NS). The addition of intravenous milrinone to captopril did not reduce mean systemic arterial pressure (71 + 8 vs 71 + 8 mm Hg) or significantly increase heart rate (89 ± 17 vs 92 ± 18 beats/min) when compared with captopril alone. Although renal blood flow was not further increased by the addition of intravenous milrinone to captopril. femoral vein oxygen content increased from 6.8 ± 1.9 to 9.9 + 1.8 ml/100 ml (p < .05). Thus simultaneous administration of captopril and milrinone has synergistic effect on cardiac performance and complementary effects on the peripheral circulation.
RECENTLY, angiotensin-converting enzyme inhibition with captopril has been shown not only to improve short-term left ventricular performance but also to enhance long-term exercise tolerance in patients with chronic congestive heart failure during long-term therapy. 11 Accordingly, therapy with captopril has gained wide acceptance for the treatment of congestive heart failure not controlled by digitalis glycosides and diuretics. However, in addition to the fact that some patients fail to benefit or have side effects from long-term captopril therapy that limit its efficacy, some patients with advanced heart failure also become increasingly symptomatic despite this therapy and thus may benefit from further inotropic support.' Milrinone, a newly synthesized, selective phosphodiesterase inhibitor that exerts disease. All patients were restricted in activity by fatigue and/or dyspnea, and not by angina, despite therapy with digitalis, diuretics, and long-acting nitrates. Mean digoxin level was 0.9 ng/ml (range 0.3 to 1.9). All patients were in functional class III or IV of the New York Heart Association for at least 3 months. All were in sinus rhythm except one patient, who was in atrial fibrillation. Their maximal oxygen uptake averaged 9.9 ml/kg/min (range 6.1 to 15.4). Left ventricular ejection fraction measured under resting conditions by gated nuclear scanning was below 20% in all patients.
The patients were admitted to the, coronary care unit at least 24 hr before the hemodynamic evaluation. Long-acting nitrates were discontinued and a 2 g sodium diet was prescribed. The patients continued to receive their usual daily doses of digitalis glycosides and diuretics during the study. The nature, potential benefits, and possible risks of the study were explained to all patients, who then gave written informed consent. The study protocol was approved in advance by the Committee on Clinical Investigations of the Albert Einstein College of Medicine.
Hemodynamic measurements. After 24 hr of bedrest, patients underwent right heart catheterization performed with flow-directed, balloon-tipped, thermodilution catheters (Edwards Laboratories). Mean pulmonary arterial, pulmonary wedge, and right atrial pressures were recorded on a photographic recorder (Electronics for Medicine). Cardiac output was determined by the thermodilution technique with 5% dextrose in water and obtained in triplicate with less than 10% variation. Systemic arterial pressure was measured via an indwelling artery catheter. Mean systemic arterial pressure was obtained by electronic integration. Derived hemodynamic variables, including cardiac index, stroke volume index, and systemic vascular resistance, were calculated from standard formulas. An electrocardiographic lead was monitored throughout the study.
Renal blood flow. Renal blood flow was determined as the left renal venous blood flow by the continuous thermodilution technique and a No. 7F dual thermistor catheter (Webster Laboratories). 1W13 The injection orifice is located 15 mm proximal to the distal end and on the concavity of the bend to prevent vascular wall contact with the opening obliquely oriented at 30 to 40 degrees against the blood stream to increase turbulence and to ensure optimal indicator/blood admixture. The external "dilution" thermistor is located 10 mm proximal to the injection orifice and the second "indicator" thermistor is within the catheter just proximal to the orifice. distally into the femoral vein. The catheter was used to withdraw blood samples while the patient was resting in a supine position. All samples were evaluated in triplicate for oxygen content (ml/100 ml) with a Lex 02-Con-TL oxygen analyzer (Lexington Instruments).
Drug administration. In the first 1 1 patients, evaluated in the postprandial state, 7.5 mug of milrinone and 12.5 mg of captopril were administered orally in variable order. Six patients received milrinone and then captopril, and five received captopril and then milrinone. Milrinone or captopril was first administered after two similar sets of control measurements were obtained 30 min apart. Systemic hemodynamic measurements were repeated at 30 min intervals for 2 hr and hourly thereafter until values returned to baseline levels. Renal blood flow and femoral vein oxygen content were measured at 30, 60, and 90 min. One of these measurements corresponded to peak increase in cardiac index in all patients. Two hours after return of the hemodynamic parameters to baseline levels, captopril or milrinone was administered and measurements were repeated as previously described. Renal and femoral vein catheters were removed immediately after completion of the study. 
Of note was the observation that resting femoral oxygen content was unchanged by captopril (8.0 ± 2.8 vs 8.1 ± 2.4 ml/100 ml) but was increased by milrinone (7.9 ± 2.6 to 9.8 ± 3.0 ml/100 ml; p < .05).
An Resting femoral vein oxygen content and renal blood flow were measured before oral administration of captopril, at peak effect of captopril, and after intravenous administration of milrinone (figure 4). Femoral vein oxygen content was unchanged by captopril (7.1 ± 1.5 vs 6.8 ± 1.9 ml/100 ml), but was increased by milrinone (9.3 ± 1.8 ml/100 ml; p < .05). Renal blood flow, which was increased by captopril (278 + 63 to 403 ± 110 ml/min; p < .05), was not further enhanced by concomitant administration of milrinone (437 ± 123 vs 403 ± 110 ml/min; p = NS).
Discussion
In this study, milrinone produced a greater improvement in cardiac performance than captopril for a similar increase in renal blood flow. Resting limb blood flow was increased by milrinone but not by captopril. In addition, concomitant administration of captopril and milrinone was safe and resulted in synergistic effects on cardiac performance and complementary effects on the peripheral circulation. mg probably would have produced greater improvement in cardiac performance. Despite the relatively low dose used in this study, milrinone increased stroke volume index substantially more than angiotensin-converting enzyme inhibition with short-term administration of captopril, while left ventricular filling pressures were reduced to a similar extent by both pharmacologic interventions.
Milrinone improves cardiac performance by enhancing myocardial contractility and directly lowering cardiac afterload. I 1`T he positive inotropic action of milrinone seems to be mediated by selective inhibition of a fraction III of cardiac phosphodiesterase that is specific for cyclic AMP.'`The vasodilating properties of milrinone most probably result from phosphodiesterase inhibition in the smooth muscle. In contrast, captopril improves cardiac performance only by lowering arterial impedance through inhibition of the production of angiotensin II and perhaps by additional mechanisms. 19 The substantial fall in systemic arterial pressure that was observed only with captopril supports the potent arteriolar vasodilator effects of the latter drug.
The hemodynamic safety of short-term intravenous administration of milrinone at the peak hemodynamic effect of captopril was documented by the absence of further reduction in systemic arterial pressure and by the lack of excessive fall in left ventricular filling pressure when compared with captopril alone. The synergistic hemodynamic effect was demonstrated by the rise in stroke volume index, which was greater than that derived with either drug administered alone. We did not determine whether a similar synergistic effect of captopril and milrinone would have been observed at a higher dose of milrinone. This study has significant implications for the use of inotropic agents vs vasodilators for the treatment of patients with chronic congestive heart failure. Blythe, 29 an excessive fall in systemic arterial pressure may, in certain instances, be responsible for a fall in renal blood flow. However, a difference in the methods used to determine renal blood flow may also help explain the discrepancy in results. Although the continuous thermodilution technique, as used in this study, allows instantaneous determination, clearance methods are not instantaneous and require a steady hemodynamic state for 60 to 160 min, which may not be present after administration of captopril. The increase in renal blood flow produced by milrinone is consistent with our prior data with amrinone30 but is at variance with the lack of changes in renal blood flow measured after 1 month of therapy with milrinone. * The lack of additional improvement in renal blood flow despite the further improvement in cardiac performance produced by intravenous administration of milrinone at the peak hemodynamic effect of captopril cannot be readily explained. The renal vasculature, which was already dilated by angiotensinconverting enzyme inhibition, may have been less sensitive to the vasodilating effect of milrinone. Consequently, the increase in cardiac output produced by milrinone may have been shunted to vascular beds where conductance could be improved, i.e., skeletal muscle. Such complementary redistribution of the increased cardiac output may be an important therapeutic benefit of combining therapy with captopril and milrnnone. 
